BMY Bristol Myers Squibb
FY2025 10-K
Bristol Myers Squibb (BMY) filed its fiscal year 2025 10-K annual report with the SEC on Feb 11, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model focused on oral immunomodulatory and oncology drugs, primarily treating multiple myeloma and CML
- • FDA-approved volume-unlimited generics launched for Revlimid (2026), pomalidomide generics entering U.S. (Mar 2026), dasatinib generics active since Sept 2024
Management Discussion & Analysis
- • Revenue and YoY change: Not disclosed in provided section
- • Profitability or margin change: Not disclosed in provided section
Risk Factors
- • FDA approval of Breyanzi in Dec 2025 for relapsed/refractory MZL after ≥2 systemic therapies, impacting market access and revenue
- • Exposure to Japan's approval landscape with multiple key drug approvals by Ministry of Health Labour and Welfare in 2025, critical for Asia Pacific growth
Financial SummaryXBRL
Revenue
$48.2B
Net Income
$7.1B
Net Margin
14.6%
ROE
38.2%
Total Assets
$90.0B
EPS (Diluted)
$3.46
Operating Cash Flow
$14.2B
Source: XBRL data from Bristol Myers Squibb FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Bristol Myers Squibb
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.